CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 2)

EP: 1.Treatment Approaches in Multiple Myeloma

EP: 2.FDA Approvals for Multiple Myeloma

EP: 3.CARTITUDE-1 Baseline Demographics

EP: 4.An Overview of CARTITUDE-1

EP: 5.CARTITUDE-1 Patients

EP: 6.CARTITUDE-1 Efficacy Findings

EP: 7.CARTITUDE-1 Safety Overview

EP: 8.CARTITUDE-1 Primary Findings Discussion

EP: 9.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)

Now Viewing

EP: 10.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 2)

With a median overall survival of more than 60 months, CARTITUDE-1 sets a new benchmark for late-line multiple myeloma therapy. The stark contrast with real-world data, where survival is closer to 12 months, emphasizes the therapy’s impact.

Notably, the safety profile remained consistent with earlier reports. There were no new instances of neurotoxicity and only a few manageable secondary malignancies and infections. Importantly, the immune recovery seen over time reduced the risk of severe infections.

This reinforces ciltacabtagene autoleucel’s value not only for efficacy but also for maintaining long-term patient health and quality of life, even in the context of heavily pretreated, immunocompromised individuals.